The Filing Desk

Bionano Genomics vs MaxCyte

Bionano Genomics BNGO · MaxCyte MXCT · Life Sciences Tools & Services

MaxCyte reported revenue of $33 million in fiscal 2025, 1.2 times Bionano Genomics' $28 million in fiscal 2025. Bionano Genomics' revenue fell 7.4% in its latest year, and MaxCyte's fell 14.5%. Bionano Genomics had an operating margin of -117.0%, against -157.1% at MaxCyte. Free cash flow was −$16 million at Bionano Genomics and −$36 million at MaxCyte.

Side by side

Bionano GenomicsMaxCyte
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$28M$33M
Revenue growth−7.4%−14.5%
Revenue growth a year, last 5 years27.4%4.7%
Gross margin46.2%81.2%
Operating margin−117.0%−157.1%
Net margin−92.6%−135.1%
Free cash flow−$16M−$36M
Free cash flow margin−57.3%−109.5%
Return on capital−89.9%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count328.4%1.5%
Last close$0.89$1.28
P/E at the last close——
Insider trades, last 12 months—bought $120,780, sold $8,316
Piotroski F-score5 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Bionano GenomicsMaxCyte
Operating margin
Percent of revenue
Bionano GenomicsMaxCyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Bionano GenomicsMaxCyte

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Bionano Genomics and MaxCyte pages.